A Phase III Clinical Trial to Study the Safety and Efficacy of MK-1293 Compared to Lantus™ in Subjects with Type 2 Diabetes Mellitus
This study is to support the development of MK-1293, a proposed follow-on insulin glargine, using Lantus™ (insulin glargine, Sanofi-aventis Pharmaceuticals, Frankfurt, Germany) as the comparator medicinal product. This study will assess the safety and efficacy of MK-1293 compared to Lantus™.
Lead Principal Investigator: Dr. Priscilla Hollander
Baylor Endocrine Center
3600 Gaston Ave.
Dallas, TX 75246
IRB Number: 013-145
| Condition | Diabetes Mellitus, Type 2, Diabetes Mellitus Types I and II |
|---|---|
| Clinical Study Identifier | TX138055 |
| Last Modified on | 21 April 2022 |
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteer
Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!
No annotations made yet
Congrats! You have your own personal workspace now.